Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer

Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 s...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 24; no. 9; pp. 2148 - 2158
Main Authors Yu, Jiangyong, Wang, Shuhang, Zhao, Wei, Duan, Jianchun, Wang, Zhijie, Chen, Hanxiao, Tian, Yanhua, Wang, Di, Zhao, Jun, An, Tongtong, Bai, Hua, Wu, Meina, Wang, Jie
Format Journal Article
LanguageEnglish
Published United States American Association for Cancer Research Inc 01.05.2018
Subjects
Online AccessGet full text
ISSN1078-0432
1557-3265
1557-3265
DOI10.1158/1078-0432.CCR-17-1932

Cover

Loading…
Abstract Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance. Experimental Design: α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined. Results: Different proportions of α2δ1+ cells were identified in SCLC cell lines and PDX models. α2δ1+ cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1+ cells instead of CD133+ cells in PDXs, and an increased proportion of α2δ1+ cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models. Conclusions: SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. Clin Cancer Res; 24(9); 2148–58. ©2018 AACR.
AbstractList Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance. Experimental Design: α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined. Results: Different proportions of α2δ1+ cells were identified in SCLC cell lines and PDX models. α2δ1+ cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1+ cells instead of CD133+ cells in PDXs, and an increased proportion of α2δ1+ cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models. Conclusions: SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. Clin Cancer Res; 24(9); 2148–58. ©2018 AACR.
Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance.Experimental Design: α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined.Results: Different proportions of α2δ1+ cells were identified in SCLC cell lines and PDX models. α2δ1+ cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1+ cells instead of CD133+ cells in PDXs, and an increased proportion of α2δ1+ cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models.Conclusions: SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. Clin Cancer Res; 24(9); 2148-58. ©2018 AACR.Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance.Experimental Design: α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined.Results: Different proportions of α2δ1+ cells were identified in SCLC cell lines and PDX models. α2δ1+ cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1+ cells instead of CD133+ cells in PDXs, and an increased proportion of α2δ1+ cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models.Conclusions: SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. Clin Cancer Res; 24(9); 2148-58. ©2018 AACR.
Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance.Experimental Design: α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined.Results: Different proportions of α2δ1+ cells were identified in SCLC cell lines and PDX models. α2δ1+ cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1+ cells instead of CD133+ cells in PDXs, and an increased proportion of α2δ1+ cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models.Conclusions: SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. Clin Cancer Res; 24(9); 2148–58. ©2018 AACR.
Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance. α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined. Different proportions of α2δ1 cells were identified in SCLC cell lines and PDX models. α2δ1 cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1 cells instead of CD133 cells in PDXs, and an increased proportion of α2δ1 cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models. SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. .
Author Zhao, Wei
Bai, Hua
Chen, Hanxiao
Yu, Jiangyong
Duan, Jianchun
Wang, Di
Wang, Jie
An, Tongtong
Wang, Shuhang
Wu, Meina
Zhao, Jun
Wang, Zhijie
Tian, Yanhua
Author_xml – sequence: 1
  givenname: Jiangyong
  surname: Yu
  fullname: Yu, Jiangyong
– sequence: 2
  givenname: Shuhang
  surname: Wang
  fullname: Wang, Shuhang
– sequence: 3
  givenname: Wei
  surname: Zhao
  fullname: Zhao, Wei
– sequence: 4
  givenname: Jianchun
  surname: Duan
  fullname: Duan, Jianchun
– sequence: 5
  givenname: Zhijie
  surname: Wang
  fullname: Wang, Zhijie
– sequence: 6
  givenname: Hanxiao
  surname: Chen
  fullname: Chen, Hanxiao
– sequence: 7
  givenname: Yanhua
  surname: Tian
  fullname: Tian, Yanhua
– sequence: 8
  givenname: Di
  surname: Wang
  fullname: Wang, Di
– sequence: 9
  givenname: Jun
  surname: Zhao
  fullname: Zhao, Jun
– sequence: 10
  givenname: Tongtong
  surname: An
  fullname: An, Tongtong
– sequence: 11
  givenname: Hua
  surname: Bai
  fullname: Bai, Hua
– sequence: 12
  givenname: Meina
  surname: Wu
  fullname: Wu, Meina
– sequence: 13
  givenname: Jie
  surname: Wang
  fullname: Wang, Jie
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29437792$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1u1TAQhS1URH_gEUCW2LBxsZ24TsQKhfIj3QqpF9hajjNpXRw72I5EX4Z3QOI5-kw47S2LbljZsr8zZ2bOIdrzwQNCzxk9Zkw0rxmVDaF1xY-77pwwSVhb8UfogAkhScVPxF653zP76DClK0pZzWj9BO3ztq6kbPkB-nUG5lJ7m7I1-PTn7ELU2QaPw4g77Q1EvM0w4Q6cw2c6fi8P34LL-gLIO5jBD-BzIZ2xS6FKKQ8O3_zmN38Y3i794m0mEwxWZxjKP0whX0LU8zU-h1RsVw9sPd5O2jlya7NZ_MXO_Cl6PGqX4NnuPEJf359-6T6SzecPn7q3G2J43XAiOGP1yKq6EQOTJ7LvjRAj7UVlysC1lMIM0rS6hbEBYEYOvO1lPw6t0aZpaHWEXt3VnWP4sUDKarLJlGa0h7AkxSnlnDayYgV9-QC9Ckv0pbtClcWv_rJQL3bU0pfx1RztpOO1ut98AcQdYGJIKcL4D2FUrQmrNT21pqdKwopJtSZcdG8e6IzNt5HlqK37j_ovhwCtTg
CitedBy_id crossref_primary_10_1007_s12035_023_03560_z
crossref_primary_10_1016_j_ceca_2022_102673
crossref_primary_10_3389_fonc_2022_899987
crossref_primary_10_1038_s41419_021_03522_0
crossref_primary_10_1016_j_bbcan_2021_188629
crossref_primary_10_1186_s12885_023_11761_x
crossref_primary_10_3390_cells11081332
crossref_primary_10_2174_1566524019666190226104909
crossref_primary_10_1007_s11864_024_01245_w
crossref_primary_10_3390_polym13081254
crossref_primary_10_1016_j_ceca_2019_05_006
crossref_primary_10_1016_j_clon_2020_05_017
crossref_primary_10_3390_cancers13102314
crossref_primary_10_1016_j_ceca_2019_05_001
crossref_primary_10_1097_JCMA_0000000000000186
crossref_primary_10_3389_fimmu_2020_01280
crossref_primary_10_3390_ijms231810687
crossref_primary_10_3390_cancers12030684
crossref_primary_10_18203_issn_2454_2156_IntJSciRep20240715
crossref_primary_10_3390_cancers11030376
crossref_primary_10_1245_s10434_021_09645_0
crossref_primary_10_3390_cells12101376
crossref_primary_10_1097_CAD_0000000000000865
crossref_primary_10_1186_s43066_020_00053_9
crossref_primary_10_1002_cac2_12351
crossref_primary_10_1245_s10434_022_11752_5
crossref_primary_10_1515_med_2021_0356
crossref_primary_10_1002_kjm2_12930
crossref_primary_10_3390_ijms20102505
crossref_primary_10_1016_j_bcp_2019_08_005
crossref_primary_10_1016_j_biopha_2023_115167
crossref_primary_10_1245_s10434_021_09647_y
crossref_primary_10_1002_cam4_4950
crossref_primary_10_1016_j_ygeno_2020_12_045
crossref_primary_10_1155_2022_3242482
crossref_primary_10_3389_fonc_2022_945896
crossref_primary_10_3233_CBM_181947
crossref_primary_10_1093_schbul_sbz114
crossref_primary_10_1002_2211_5463_13230
crossref_primary_10_1038_s41392_022_01150_4
crossref_primary_10_1016_j_ceca_2019_04_005
crossref_primary_10_1371_journal_pone_0279186
crossref_primary_10_1007_s00535_024_02095_x
Cites_doi 10.1016/S0002-9440(10)62276-6
10.1016/j.ccr.2013.02.025
10.1155/2015/137981
10.1016/j.freeradbiomed.2012.03.024
10.1111/cas.12045
10.1002/1097-0142(19900415)65:8<1678::AID-CNCR2820650803>3.0.CO;2-N
10.1073/pnas.0905653106
10.1038/labinvest.2013.92
10.1186/s12943-016-0501-y
10.1016/j.nbd.2010.11.001
10.1002/stem.2473
10.1101/gr.133744.111
10.1038/nature03128
10.1093/bioinformatics/btu638
10.1093/bioinformatics/btp120
10.1371/journal.pone.0125255
10.1371/journal.pone.0057020
10.1007/s12015-007-9002-0
10.1038/nrclinonc.2012.61
10.1111/j.1349-7006.2009.01144.x
10.1158/0008-5472.CAN-10-3126
10.1158/1078-0432.CCR-07-0932
10.1111/cas.12860
10.1158/0008-5472.CAN-06-3126
10.1073/pnas.0530291100
10.1186/gb-2010-11-10-r106
10.1007/s00441-004-1018-z
10.1111/1759-7714.12291
10.1002/ar.a.10019
10.1016/S0021-9258(18)77174-3
10.1038/sj.cdd.4402283
10.1038/nmeth.1923
10.1158/0008-5472.CAN-13-1541
10.1007/s12094-010-0540-6
10.1007/s004320100289
10.1101/gad.262998.115
10.1038/sj.onc.1207097
ContentType Journal Article
Copyright 2018 American Association for Cancer Research.
Copyright American Association for Cancer Research Inc May 1, 2018
Copyright_xml – notice: 2018 American Association for Cancer Research.
– notice: Copyright American Association for Cancer Research Inc May 1, 2018
DBID AAYXX
CITATION
NPM
7QO
7T5
7TO
7U9
8FD
FR3
H94
P64
7X8
DOI 10.1158/1078-0432.CCR-17-1932
DatabaseName CrossRef
PubMed
Biotechnology Research Abstracts
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Virology and AIDS Abstracts
Biotechnology Research Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
Virology and AIDS Abstracts
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 2158
ExternalDocumentID 29437792
10_1158_1078_0432_CCR_17_1932
Genre Journal Article
GroupedDBID ---
18M
29B
2FS
2WC
34G
39C
53G
5GY
5RE
5VS
6J9
AAFWJ
AAJMC
AAYXX
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
AFUMD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BR6
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
OK1
P0W
P2P
QTD
RCR
RHI
RNS
SJN
TR2
W2D
W8F
WOQ
YKV
NPM
7QO
7T5
7TO
7U9
8FD
FR3
H94
P64
7X8
ID FETCH-LOGICAL-c2482-52114f13485d1767bbc55f0b53c1044775cd7c9a9ef8ee1c7d29b7bfd9cac8803
ISSN 1078-0432
1557-3265
IngestDate Thu Jul 10 18:21:53 EDT 2025
Sat Jul 26 02:18:27 EDT 2025
Thu Apr 03 07:02:00 EDT 2025
Tue Jul 01 01:30:14 EDT 2025
Thu Apr 24 22:54:05 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
License 2018 American Association for Cancer Research.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2482-52114f13485d1767bbc55f0b53c1044775cd7c9a9ef8ee1c7d29b7bfd9cac8803
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 29437792
PQID 2032617677
PQPubID 2046235
PageCount 11
ParticipantIDs proquest_miscellaneous_2002208731
proquest_journals_2032617677
pubmed_primary_29437792
crossref_primary_10_1158_1078_0432_CCR_17_1932
crossref_citationtrail_10_1158_1078_0432_CCR_17_1932
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-05-01
PublicationDateYYYYMMDD 2018-05-01
PublicationDate_xml – month: 05
  year: 2018
  text: 2018-05-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Philadelphia
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2018
Publisher American Association for Cancer Research Inc
Publisher_xml – name: American Association for Cancer Research Inc
References Schuller (2022061102014617400_bib35) 2003; 270
Florek (2022061102014617400_bib10) 2005; 319
Uchida (2022061102014617400_bib12) 2016; 107
Zhao (2022061102014617400_bib18) 2013; 23
Ghosh (2022061102014617400_bib33) 2015; 2015
Sullivan (2022061102014617400_bib13) 2011; 41
Kubo (2022061102014617400_bib17) 2013; 104
Burger (2022061102014617400_bib36) 2003; 22
Kwon (2022061102014617400_bib37) 2015; 29
Williams (2022061102014617400_bib30) 2013; 93
Ries LAG (2022061102014617400_bib1) 2007
Wang (2022061102014617400_bib5) 2013; 8
Anders (2022061102014617400_bib22) 2015; 31
Anders (2022061102014617400_bib24) 2012; 22
Eramo (2022061102014617400_bib3) 2008; 15
Zeppernick (2022061102014617400_bib8) 2008; 14
Trapnell (2022061102014617400_bib21) 2009; 25
De Jongh (2022061102014617400_bib26) 1990; 265
Anderson (2022061102014617400_bib31) 2015; 10
Tentler (2022061102014617400_bib28) 2012; 9
Veeramani (2022061102014617400_bib32) 2012; 53
Langmead (2022061102014617400_bib20) 2012; 9
Fukuoka (2022061102014617400_bib2) 1990; 65
Clarke (2022061102014617400_bib4) 2006; 66
Sales (2022061102014617400_bib6) 2007; 3
Barnawi (2022061102014617400_bib27) 2016; 34
Meng (2022061102014617400_bib16) 2009; 100
Singh (2022061102014617400_bib11) 2004; 432
Al-Hajj (2022061102014617400_bib7) 2003; 100
Bertolini (2022061102014617400_bib15) 2009; 106
Fu (2022061102014617400_bib25) 2016; 7
Falcon (2022061102014617400_bib19) 2011; 71
Jull (2022061102014617400_bib34) 2001; 127
Anders (2022061102014617400_bib23) 2010; 11
Ciccarelli (2022061102014617400_bib38) 2016; 15
Bussolati (2022061102014617400_bib9) 2005; 166
Sarvi (2022061102014617400_bib14) 2014; 74
Jin (2022061102014617400_bib29) 2010; 12
References_xml – volume-title: SEER Cancer Statistics Review, 1975–2004
  year: 2007
  ident: 2022061102014617400_bib1
– volume: 166
  start-page: 545
  year: 2005
  ident: 2022061102014617400_bib9
  article-title: Isolation of renal progenitor cells from adult human kidney
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)62276-6
– volume: 23
  start-page: 541
  year: 2013
  ident: 2022061102014617400_bib18
  article-title: 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel alpha2delta1 subunit
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.02.025
– volume: 2015
  start-page: 137981
  year: 2015
  ident: 2022061102014617400_bib33
  article-title: Characterization of Toll-like receptor-4 (TLR-4) in the spleen and thymus of Swiss albino mice and its modulation in experimental endotoxemia
  publication-title: J Immunol Res
  doi: 10.1155/2015/137981
– volume: 53
  start-page: 95
  year: 2012
  ident: 2022061102014617400_bib32
  article-title: Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2012.03.024
– volume: 104
  start-page: 78
  year: 2013
  ident: 2022061102014617400_bib17
  article-title: Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy
  publication-title: Cancer Sci
  doi: 10.1111/cas.12045
– volume: 65
  start-page: 1678
  year: 1990
  ident: 2022061102014617400_bib2
  article-title: Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of a 5-year follow-up
  publication-title: Cancer
  doi: 10.1002/1097-0142(19900415)65:8<1678::AID-CNCR2820650803>3.0.CO;2-N
– volume: 106
  start-page: 16281
  year: 2009
  ident: 2022061102014617400_bib15
  article-title: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0905653106
– volume: 93
  start-page: 970
  year: 2013
  ident: 2022061102014617400_bib30
  article-title: Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century
  publication-title: Lab Invest
  doi: 10.1038/labinvest.2013.92
– volume: 15
  start-page: 16
  year: 2016
  ident: 2022061102014617400_bib38
  article-title: Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population
  publication-title: Mol Cancer
  doi: 10.1186/s12943-016-0501-y
– volume: 41
  start-page: 552
  year: 2011
  ident: 2022061102014617400_bib13
  article-title: Effect of epithelial stem cell transplantation on noise-induced hearing loss in adult mice
  publication-title: Neurobiol Dis
  doi: 10.1016/j.nbd.2010.11.001
– volume: 34
  start-page: 2799
  year: 2016
  ident: 2022061102014617400_bib27
  article-title: Fascin is critical for the maintenance of breast cancer stem cell pool predominantly via the activation of the notch self-renewal pathway
  publication-title: Stem Cells
  doi: 10.1002/stem.2473
– volume: 22
  start-page: 2008
  year: 2012
  ident: 2022061102014617400_bib24
  article-title: Detecting differential usage of exons from RNA-seq data
  publication-title: Genome Res
  doi: 10.1101/gr.133744.111
– volume: 432
  start-page: 396
  year: 2004
  ident: 2022061102014617400_bib11
  article-title: Identification of human brain tumour initiating cells
  publication-title: Nature
  doi: 10.1038/nature03128
– volume: 31
  start-page: 166
  year: 2015
  ident: 2022061102014617400_bib22
  article-title: HTSeq–a Python framework to work with high-throughput sequencing data
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btu638
– volume: 25
  start-page: 1105
  year: 2009
  ident: 2022061102014617400_bib21
  article-title: TopHat: discovering splice junctions with RNA-Seq
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btp120
– volume: 10
  start-page: e0125255
  year: 2015
  ident: 2022061102014617400_bib31
  article-title: Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0125255
– volume: 8
  start-page: e57020
  year: 2013
  ident: 2022061102014617400_bib5
  article-title: Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0057020
– volume: 3
  start-page: 249
  year: 2007
  ident: 2022061102014617400_bib6
  article-title: Stem cells and cancer: an overview
  publication-title: Stem Cell Rev
  doi: 10.1007/s12015-007-9002-0
– volume: 9
  start-page: 338
  year: 2012
  ident: 2022061102014617400_bib28
  article-title: Patient-derived tumour xenografts as models for oncology drug development
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2012.61
– volume: 100
  start-page: 1040
  year: 2009
  ident: 2022061102014617400_bib16
  article-title: Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2009.01144.x
– volume: 71
  start-page: 1573
  year: 2011
  ident: 2022061102014617400_bib19
  article-title: Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-3126
– volume: 14
  start-page: 123
  year: 2008
  ident: 2022061102014617400_bib8
  article-title: Stem cell marker CD133 affects clinical outcome in glioma patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-0932
– volume: 107
  start-page: 353
  year: 2016
  ident: 2022061102014617400_bib12
  article-title: Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment
  publication-title: Cancer Sci
  doi: 10.1111/cas.12860
– volume: 66
  start-page: 9339
  year: 2006
  ident: 2022061102014617400_bib4
  article-title: Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-3126
– volume: 100
  start-page: 3983
  year: 2003
  ident: 2022061102014617400_bib7
  article-title: Prospective identification of tumorigenic breast cancer cells
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0530291100
– volume: 11
  start-page: R106
  year: 2010
  ident: 2022061102014617400_bib23
  article-title: Differential expression analysis for sequence count data
  publication-title: Genome Biol
  doi: 10.1186/gb-2010-11-10-r106
– volume: 319
  start-page: 15
  year: 2005
  ident: 2022061102014617400_bib10
  article-title: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer
  publication-title: Cell Tissue Res
  doi: 10.1007/s00441-004-1018-z
– volume: 7
  start-page: 100
  year: 2016
  ident: 2022061102014617400_bib25
  article-title: High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies
  publication-title: Thorac Cancer
  doi: 10.1111/1759-7714.12291
– volume: 270
  start-page: 51
  year: 2003
  ident: 2022061102014617400_bib35
  article-title: Receptor-mediated effects of nicotine and its nitrosated derivative NNK on pulmonary neuroendocrine cells
  publication-title: Anat Rec A Discov Mol Cell Evol Biol
  doi: 10.1002/ar.a.10019
– volume: 265
  start-page: 14738
  year: 1990
  ident: 2022061102014617400_bib26
  article-title: Subunits of purified calcium channels. Alpha 2 and delta are encoded by the same gene
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)77174-3
– volume: 15
  start-page: 504
  year: 2008
  ident: 2022061102014617400_bib3
  article-title: Identification and expansion of the tumorigenic lung cancer stem cell population
  publication-title: Cell Death Differ
  doi: 10.1038/sj.cdd.4402283
– volume: 9
  start-page: 357
  year: 2012
  ident: 2022061102014617400_bib20
  article-title: Fast gapped-read alignment with Bowtie 2
  publication-title: Nat Methods
  doi: 10.1038/nmeth.1923
– volume: 74
  start-page: 1554
  year: 2014
  ident: 2022061102014617400_bib14
  article-title: CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-1541
– volume: 12
  start-page: 473
  year: 2010
  ident: 2022061102014617400_bib29
  article-title: Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review
  publication-title: Clin Translat Oncol
  doi: 10.1007/s12094-010-0540-6
– volume: 127
  start-page: 707
  year: 2001
  ident: 2022061102014617400_bib34
  article-title: Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s004320100289
– volume: 29
  start-page: 1587
  year: 2015
  ident: 2022061102014617400_bib37
  article-title: Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis
  publication-title: Gene Dev
  doi: 10.1101/gad.262998.115
– volume: 22
  start-page: 8093
  year: 2003
  ident: 2022061102014617400_bib36
  article-title: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207097
SSID ssj0014104
Score 2.2539928
Snippet Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving...
Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 2148
SubjectTerms Biotechnology
Calcium
Calcium channels (voltage-gated)
Cancer
Cell culture
Cell self-renewal
Chemoresistance
Chemotherapy
Drug resistance
Electric potential
Experimental design
Gene expression
Lung cancer
Monoclonal antibodies
Properties (attributes)
Small cell lung carcinoma
Stem cells
Western blotting
Xenografts
Xenotransplantation
Title Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/29437792
https://www.proquest.com/docview/2032617677
https://www.proquest.com/docview/2002208731
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELbKIiEuiH8KCzISe6pSGsepkyOELivUXSTUQjlFieOwldIU7TYHeBhOvAASz7HPxIzt_CxbxMIlrdwmtvJ9Gc9M5oeQZyMv5S7DOL-EK4dnaeqEocycxAvHMmcZWBS62ufR-GDO3yz8Ra_3vRO1VG3Sofy6Na_kf1CFMcAVs2T_AdnmojAA3wFfOALCcLwUxocK83Z1qeWBCaZrFMAI0TzBIK7VIEL_HCblwMD7dbEBEeK8ss1vN5idJZfVSucZlKoY7EWTvZcu0x_cRclSwWPv6BQTVE-xxIBN20L9_RQVUJQOSxAUq6QoHD3dtMJ4Ar2Irv4b1YmY0qzP1hpqfNIfK00r4OynL2u7qWp3v_VqH1fo4O54u7Wn94Natgq58ejiJeRxVXa9Gm7QxhDWgtgH4cdMH4mh2jJmpbfJwLYsDc-JYlPC8-Ie4QfaXYGlhbnHhlH0zoGtGjXZdlOsAwGO3sb78-k0nk0WsyvkKgNjBPtkvF40gUQYKKtjF-rV2TwxmOb51knOa0B_MGu0ejO7SW5Yu4S-MCS7RXqqvE2uHdrIizvkW4drtMM1us6pgZki1yiCTw3X6AWuUcs1arlGz36ws58u_Z1jtMsx2nKMLkvacowix-zkd8l8fzKLDhzb28ORjAfo_wBDPHc9HviZK8YiTaXv56PU9yTcTi6ELzMhwyRUeaCUK0XGwlSkeRbKRMKe490jO-W6VA8IlRxdPFL4Ict4wkehHAuRi0wGCdjr47xPeH2_Y2kL32P_lSLWBrAfxAhTjDDFAFPsihhh6pNhc9pnU_nlbyfs1mDGVkicxmzkYc8DWFGfPG1-BhGO7-WSUq0r_A-muwfCc_vkviFBMyMLOZYEZQ8vcfYjcr19lHbJzuakUo9BZd6kTzRjfwEa4L_G
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanistic+Exploration+of+Cancer+Stem+Cell+Marker+Voltage-Dependent+Calcium+Channel+%CE%B12%CE%B41+Subunit-mediated+Chemotherapy+Resistance+in+Small-Cell+Lung+Cancer&rft.jtitle=Clinical+cancer+research&rft.au=Yu%2C+Jiangyong&rft.au=Wang%2C+Shuhang&rft.au=Zhao%2C+Wei&rft.au=Duan%2C+Jianchun&rft.date=2018-05-01&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=24&rft.issue=9&rft.spage=2148&rft_id=info:doi/10.1158%2F1078-0432.CCR-17-1932&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon